Johns Hopkins HIV Guide
Bictegravir
INDICATIONS
FDA
FDA
Treatment of ART-naive patients or those that are virologically suppressed on an ART regimen for at least 3 months
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 4, 2018
Citation
Smith, Janessa M. "Bictegravir." Johns Hopkins HIV Guide, The Johns Hopkins University, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545270/all/Bictegravir.
Smith JM. Bictegravir. Johns Hopkins HIV Guide. The Johns Hopkins University; 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545270/all/Bictegravir. Accessed October 8, 2025.
Smith, J. M. (2018). Bictegravir. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545270/all/Bictegravir
Smith JM. Bictegravir [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2018. [cited 2025 October 08]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545270/all/Bictegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Bictegravir
ID - 545270
A1 - Smith,Janessa,Pharm.D., BCPS
Y1 - 2018/06/04/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545270/all/Bictegravir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
